| Drug Name | Imatinib |
|---|---|
| Other Drug Names | CGP 57148; CGP 57148B; CTI 571; Gleevec; Glivec; Imatinib mesilate; Imatinib mesylate; QTI 571; Ruvise; STI 571 |
| Chemical Name | α-(4-methyl-1-piperazinyl)-3'-[[4-(3-pyridyl)-2-pyrimidinyl]amino]-p-tolu-p-toluidide |
| Formula | C29H31N7O |
| Mol. Wt. | 493.61 |
| CAS No. | 152459-95-5 |
| UNII | BKJ8M8G5HI |
| Target-based Actions | Abl tyrosine kinase inhibitor; Bcr protein inhibitor; Kit tyrosine kinase inhibitor; PDGF receptor antagonist; Signal transduction inhibitor |
| ATC Codes | L01XE01 |
| Highest Status | 2001年批准上市 |
| Originator Company | NOVARTIS PHARMACEUTICALS CORP |
| Structure |
 |